{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-029310","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2024-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.458973+00:00","generated_at":"2026-05-31T04:50:34.952548+00:00","sec_items":["1.02","2.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp","bullets":["Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.","Acquired assets generate ~$100M annual revenue; OPKO retains NY/NJ and oncology/urology ($400M).","BioReference repaid $9.7M credit facility with JPMorgan; no prepayment penalty.","Pro forma cash increases to ~$273M; estimated gain on sale ~$122.6M.","OPKO Chairman cites transaction as key step toward profitability and focus on core testing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-029310","json":"https://secwatch.observer/filing/0001437749-24-029310.json","markdown":"https://secwatch.observer/filing/0001437749-24-029310.md","text":"https://secwatch.observer/filing/0001437749-24-029310.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/0001437749-24-029310-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:50:34.952548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}